US Pharma MarketingWhereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.
Viridian data lift prospects for thyroid eye disease drug
<figure><div><img src="https://imgproxy.divecdn.com/egbyTu8esim-VjYj5FTvMQUlBrndW-s35OSn02s-EoY/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzk4NTE5MTYzLmpwZw==.webp"/></div></figure><p>Whereas earlier Ph
Source: BioPharma Dive